Skip to main content
. 2017 Jul 31;7:6882. doi: 10.1038/s41598-017-07358-7

Figure 2.

Figure 2

Sankey diagram representing the distribution of FDA drug approvals for which all trials included biomarker-positive patients (ie, enriched), the number of approvals with at least one non-enriched randomized controlled trial and the statistical significance of the treatment-by-biomarker interaction. Width of links is proportional to the number of approvals.